A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)

• Status: Completed
• Trial end date: 2005-09-28
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Alendronate; Risedronate Sodium; Risedronic Acid

Criteria

Inclusion Criteria:

• Postmenopausal women with osteoporosis

Exclusion Criteria:

• Any known allergy to the study drug